Author Archives: donttradeourlivesaway

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Study published in BMJ shows that expenditure on medicines constitutes the single largest component of the total Out of Pocket payments by households

Thirty-eight million people slipped into poverty owing to expenses on medicines in year 2011-12. Just for perspective, poverty line in rural India is USD 11.82 a month, and for urban India it is calculated at 14.48 a month. Click here … Continue reading

Posted in Uncategorized | Leave a comment

Here’s the short note on UNHLM on TB and US pressurising to dilute TRIPS flexibilities

The United Nations is going to hold a High Level Meeting on TB in New York in September. The member countries of UN will sign on a declaration will set the direction in which work on TB, globally, will move. … Continue reading

Posted in TRIPS, TRIPS flexibilities, Tuberculosis (TB), US Pressure | Leave a comment

Quick Takeaways from #AffordableMedsNow Conference

18th July 2018, New Delhi Source: Pens and Needles 🔊 Listen to Post Last week, Public Citizen hosted the “Affordable Medicines Now” conference at Georgetown Law in Washington, DC. The event, organized by Public Citizen’s Justin Mendoza (@JustinDMendoza), featured three … Continue reading

Posted in Access to Medecines | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

Intellectual Property rules stand amended

Source: The Hindu | July 02, 2018 Some powers with Customs revoked The Union Ministry of Finance has amended Intellectual Property rules to revoke the power vested with Customs authorities to seize imported products based on complaints of patent infringement. … Continue reading

Posted in IPR Enforcement, IPR policy, Patent infringement | Leave a comment